Publications
861
Citations
49,448
Est. group size
~2
Recurring co-author estimate
Active years
30
Publishing since 1997
Typically publishes in teams of ~15 · 5% small-team papers (≤3 authors) · across 60 venues
- Asciminib monotherapy in patients with BCR::ABL1 T315I-mutated chronic-phase chronic myeloid leukemia: phase 1 trial final results
Leukemia · 2026
- Single agent selinexor is active in patients with myelofibrosis refractory or intolerant to JAK inhibitors
Blood Cancer Journal · 2026
- 2025 European LeukemiaNet recommendations for the management of chronic myeloid leukemia
Leukemia · 2025
- KIT-Targeting Drugs in the Management of Nonadvanced and Advanced Systemic Mastocytosis
The Journal of Allergy and Clinical Immunology In Practice · 2025
- The small GTPase ARF6 regulates sphingolipid homeostasis and supports proliferation in acute myeloid leukemia
Haematologica · 2025
- Disease-Modifying Effects of Avapritinib in Patients with Advanced Systemic Mastocytosis: Improvements in Bone Density
Osteologie/Osteology · 2025
- POSTER: CML-1107 Asciminib Demonstrates Comparable Tolerability and Efficacy With Once-Daily (QD) and Twice-Daily (BID) Dosing in Chronic Myeloid Leukemia in Chronic Phase (CML-CP): Final Analysis (Week 72) of the Phase 3b AIM4CML Trial
Clinical Lymphoma Myeloma & Leukemia · 2025
- MPN-569: Apex Part 1: Updated Assessment of Bezuclastinib (CGT9486), a Selective KIT D816V Tyrosine Kinase Inhibitor, in Patients with Advanced Systemic Mastocytosis
Clinical Lymphoma Myeloma & Leukemia · 2025
- POSTER: MPN-569 Apex Part 1: Updated Assessment of Bezuclastinib (CGT9486), a Selective KIT D816V Tyrosine Kinase Inhibitor, in Patients with Advanced Systemic Mastocytosis
Clinical Lymphoma Myeloma & Leukemia · 2025
- CML-1107: Asciminib Demonstrates Comparable Tolerability and Efficacy With Once-Daily (QD) and Twice-Daily (BID) Dosing in Chronic Myeloid Leukemia in Chronic Phase (CML-CP): Final Analysis (Week 72) of the Phase 3b AIM4CML Trial
Clinical Lymphoma Myeloma & Leukemia · 2025
- Special considerations in the management of adult patients with acute leukaemias and myeloid neoplasms in the COVID-19 era: recommendations from a panel of international experts
UNC Libraries · 2025
- Enhanced tyrosine kinase inhibitor response on chronic myeloid leukemia cells upon MS4A3 mRNA delivery
Blood · 2025
- Avapritinib treatment of patients with advanced systemic mastocytosis: 4-year safety, effect on bone and first-line efficacy results of the pathfinder clinical study
Blood · 2025
- Effect of avapritinib on skin lesions in patients with advanced systemic mastocytosis using a novel, artificial intelligence-based technology
Blood · 2025
- Asciminib monotherapy in patients with chronic-phase chronic myeloid leukemia with the T315I mutation after ≥1 prior tyrosine kinase inhibitor: 2-year follow-up results
Leukemia · 2024
- Blood×115
- Clinical Lymphoma Myeloma & Leukemia×55
- Leukemia×25
- Journal of Clinical Oncology×17
- Haematologica×10
- Moshe Talpaz
Medicine · University of Michigan
- Christopher Davis
Medicine · Indiana University
- Ravi Bhatia
Medicine · University of Michigan
- Taylor K. Johnson
Medicine · University of Michigan
- Xiaoling Xuei
Medicine · Indiana University
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 25, 2026.
Claim or correct this profile